A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.

摘要: Purpose: Irinotecan and capecitabine have synergistic antitumor activity with distinct mechanisms of action but without overlapping major toxicity. We conducted a Phase II study to evaluate the efficacy weekly irinotecan plus in patients previously treated non-small cell lung cancer (NSCLC). Experimental Design: Eligible had received at least one prior chemotherapy regimen. The treatment consisted (90–100 mg/m 2 i.v.) on days 1 8 (1000 p.o. b.i.d.) 1–14 21-day cycle. Treatment was given until disease progression or unacceptable toxicity Results: Thirty-seven median age 59 years were enrolled. Eighteen (49%) regimen, 19 (51%) two more regimens. Initial 5 100 grade 3 diarrhea seen patients, subsequent 32 90 irinotecan. Four (11.4%) 35 evaluable partial response 12 (34.3%) stable disease. There no complete response. All responses noted who regimen (4 18, 22%), there among Median duration 5.6 months (range, 5–8.7 months). At follow-up 6 months, survival 7.4 (95% confidence interval, 3.6–9.0). Grade 4 toxicities neutropenia (12%), anemia (13%), (12%) dose level . Conclusions: Weekly favorable profile as second-line for recurrent NSCLC. This may provide an additional option advanced